Compare CPHI & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPHI | DRCT |
|---|---|---|
| Founded | N/A | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.9M |
| IPO Year | N/A | 2022 |
| Metric | CPHI | DRCT |
|---|---|---|
| Price | $1.53 | $0.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 47.5K | ★ 24.1M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,052,266.00 | ★ $35,369,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.20 | $0.07 |
| 52 Week High | $3.35 | $6.59 |
| Indicator | CPHI | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 21.95 |
| Support Level | $1.41 | $0.09 |
| Resistance Level | $1.88 | $0.09 |
| Average True Range (ATR) | 0.14 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 29.79 | 1.33 |
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.